UPDATE: Jefferies Initates Coverage on BioScrip With a Buy Rating on Likely EBITDA Growth

In a report published on Tuesday, Jefferies analyst Brian Tanquilut initated coverage on BioScrip BIOS with a Buy Rating and a $17.00 price target.

In the report, Jefferies pointed out, "Our positive view on BIOS is driven primarily by our expectation for sustained, robust top line and EBITDA growth over the next five years. BIOS has demonstrated its ability to sustain organic growth of ~20% in its core infusion business over the last five quarters, and we expect the company to sustain this trajectory for the next several years as demand for home/alternate site infusion services continues to grow and BIOS gains incremental market share."

BioScrip closed on Monday at $13.21.